ASSEMBLY BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $380.09M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | During market hours | $13.40M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $8.20M | $-0.54 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | During market hours | $10.80M | $-0.72 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $9.60M | $-1.33 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $9.40M | $-1.17 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $6.80M | $-1.51 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | $8.50M | $-1.98 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | During market hours | – | – | – |
Press releases
Announcements Assembly Biosciences filed with the SEC
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K/A
Assembly Biosciences Announces Pricing of $100 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Material agreement · Other events · EX-99.2 to Form 8-K
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
Results of operations · Other events · EX-99.1 to Form 8-K
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Results of operations · Other events · EX-99.2 to Form 8-K
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K
Ass embly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Announces Effective Date of Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
Results of operations · EX-99 to Form 8-K
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
Results of operations · Other events · EX-99 to Form 8-K
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
Results of operations · EX-99.1 to Form 8-K
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Announces Program Reprioritization and Organizational Update
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
Other events · EX-99.1 to Form 8-K
Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K